Stockreport

Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD

Fulcrum Therapeutics, Inc.  (FULC) 
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am Check Earnings Report
PDF CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the live [Read more]